A part of Watch Media

MedWatchWednesday1 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
20/12/2022at 12:35

Swedish antibiotic research center bulks up collaboration

Next year, Sweden’s Center for Antibiotic Resistance Research (CARe) will count three universities, close to 150 researchers, and more than 20 institutions.
Photo: Torben Stroyer/Jyllands-Posten/Ritzau Scanpix
by albert rønning-andersson, translated by daniel pedersen

Drug-resistant bacteria are one of the world’s biggest health threats. More than a million people die each year due to antimicrobial resistance (AMR).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Nancy Pelosi, current speaker of the House of Representatives | Photo: LEAH MILLIS/REUTERS / X90205

    US pharma industry urges official action against antimicrobial resistance

    For subscribers

  • Photo: Daniel Karmann/AP/Ritzau Scanpix

    Drugmakers aim to curb release of antibiotic waste into the environment

    For subscribers

  • Charlotte Dyring, newly appointed CEO of Pincer Biotech | Photo: Privat / Charlotte Dyring

    Pincer Biotech appoints CEO, cementing goal to combat antibiotic resistance

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Arnd Wiegmann/Reuters/Ritzau Scanpix
Pharma & biotech

Novartis beats Kesimpta sales expectations in Q4

Multiple sclerosis treatment Kesimpta, based on Genmab-developed ofatumumab, has generated more than analysts predicted in Q4’22.
  • Janssen's books disappointing sales of Genmab-developed Darzalex
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Analyst: Strong Novo Nordisk outlook should satisfy investors

For subscribers

Foto: Jens Dresling/Ritzau Scanpix
Pharma & biotech

Studies of Wegovy in higher-than-approved doses begin

For subscribers

Foto: Novo Nordisk
Pharma & biotech

Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk meets upgraded guidance, setting new revenue record

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

Novo Nordisk doubles obesity sales in 2022

For subscribers

Further reading

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk predicts wide range for 2023 sales growth

The Danish drugmaker has released its 2023 guidance with a sales growth expectation of 13–19%. (Updated)

For subscribers

Foto: Robert Galbraith/Reuters/Ritzau Scanpix
Pharma & biotech

Amgen takes on Abbvie blockbuster Humira with unusual price plan

Abbvie’s multibillion-dollar generating anti-inflammatory drug, Humira, is about to face competition for the first time, as Amgen launches an almost identical product using an unconventional strategy.

For subscribers

Foto: Peter Klint/Politiken/Ritzau Scanpix
Pharma & biotech

US fails to pass Netflix-style model for new antibiotics – "a huge disappointment"

Right before the finish line, officials in the US elected not to vote on the PASTEUR Act, which would have changed, and boosted, how antibiotic development is funded.

For subscribers

Latest news

  • Novartis beats Kesimpta sales expectations in Q4 – 11:49
  • Analyst: Strong Novo Nordisk outlook should satisfy investors – 11:09
  • Studies of Wegovy in higher-than-approved doses begin – 10:01
  • Rare Disease business comes in slightly below expectations for Novo Nordisk – 09:48
  • Novo Nordisk meets upgraded guidance, setting new revenue record – 09:20
  • Novo Nordisk doubles obesity sales in 2022 – 08:54
  • Maersk and German start-up wants to enhance emission visibility for global e-trade – 08:27
  • Novo Nordisk predicts wide range for 2023 sales growth – 07:38
  • Pfizer hopes Covid-19 sales will increase in the long run – 31 Jan
  • Amgen takes on Abbvie blockbuster Humira with unusual price plan – 31 Jan
See all

Jobs

  • Commercial Director

  • Clinical Operational Associate

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Lead Data Architect

  • Experienced Patent Counsel

  • Sr. Director, Drug Safety Physician

  • Regulatory Affairs Professional

  • Application Manager

  • Head of Regulatory Affairs Danmark

  • Senior Regulatory Affairs Professional

  • Application Manager

See all jobs

Jobs

  • Commercial Director

  • Clinical Operational Associate

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Lead Data Architect

  • Experienced Patent Counsel

  • Sr. Director, Drug Safety Physician

  • Regulatory Affairs Professional

  • Application Manager

  • Head of Regulatory Affairs Danmark

  • Senior Regulatory Affairs Professional

  • Application Manager

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge